JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

74.73 0.04

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

74

Max

75.05

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-100M

-229M

Pardavimai

46M

203M

Pelno marža

-112.808

Darbuotojai

1,402

EBITDA

4.7B

4.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+38.63% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.3B

12B

Ankstesnė atidarymo kaina

74.69

Ankstesnė uždarymo kaina

74.73

Naujienos nuotaikos

By Acuity

50%

50%

163 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-21 23:27; UTC

Svarbiausios naujienos

BHP Expects Annual Copper Output in Upper Half of Guidance, Finishes China Iron-Ore Negotiations

2026-04-21 23:27; UTC

Karštos akcijos

Stocks to Watch: Sonoco Products, Adobe, Manhattan Associates, Target Hospitality

2026-04-21 23:02; UTC

Uždarbis

Correction to Capital One Financial 1Q Earnings Article

2026-04-21 23:47; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-21 23:47; UTC

Rinkos pokalbiai

Nikkei May Decline as Hopes for U.S.-Iran Peace Talks Fade -- Market Talk

2026-04-21 23:36; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Market Talk Roundup: Latest on U.S. Politics

2026-04-21 23:36; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Higher After Trump Says U.S. Will Extend Cease-Fire Deadline -- Market Talk

2026-04-21 23:32; UTC

Uždarbis

America Movil 1Q EBITDA MXN94.5B, Up 3.8% on Year >AMX

2026-04-21 23:30; UTC

Uždarbis

America Movil 1Q Rev MXN236.84B, Up 2.1% on Year >AMX

2026-04-21 23:28; UTC

Uždarbis

America Movil 1Q Net MXN23.4B Vs. Net MXN18.7B >AMX

2026-04-21 23:16; UTC

Svarbiausios naujienos

Ampol Entered 2Q With Hedge Book Positioned to Mitigate Volatility

2026-04-21 23:15; UTC

Svarbiausios naujienos

Ampol Entered 2Q With Broad-Based Momentum

2026-04-21 23:15; UTC

Svarbiausios naujienos

Ampol: Suitable Crudes for Lytton Remain Available in Market

2026-04-21 23:14; UTC

Svarbiausios naujienos

Ampol: Crude Supplies Secured Into July

2026-04-21 23:14; UTC

Svarbiausios naujienos

Ampol: Fuel Supplies Secured Until at Least End of May

2026-04-21 23:13; UTC

Svarbiausios naujienos

Ampol: Well Placed for Crude, Product Supply Prior to Iran Conflict

2026-04-21 23:13; UTC

Svarbiausios naujienos

Ampol 1Q Lytton Refinery Production 1.43 Billion Liters

2026-04-21 23:12; UTC

Svarbiausios naujienos

Ampol 1Q Lytton Refiner Margin US$25.45/Bbl

2026-04-21 22:54; UTC

Rinkos pokalbiai

Sell America Trade Could Gain Momentum If Fed Uncertainty Unresolved -- Market Talk

2026-04-21 22:49; UTC

Svarbiausios naujienos

BHP 3Q Average Realized Energy Coal Price $105.61/Ton, Up 10% On-Quarter

2026-04-21 22:49; UTC

Svarbiausios naujienos

BHP 3Q Average Realized Steelmaking Coal Price $226.76/Ton, Up 15% On-Quarter

2026-04-21 22:48; UTC

Svarbiausios naujienos

BHP 3Q Average Realized Iron Ore Price $85.35/Ton, Flat On-Quarter

2026-04-21 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Alliance Portfolio Is Comprised of Five Plants: Batavia, Hillburn, Massena, Shoemaker and Sterling

2026-04-21 22:48; UTC

Svarbiausios naujienos

BHP 3Q Average Realized Copper Price $5.86/Pound, Down 1% On-Quarter

2026-04-21 22:48; UTC

Įsigijimai, susijungimai, perėmimai

PowerTransitions to Buy 323 MW of Power Generation Assets in New York State From Alliance Energy Group

2026-04-21 22:46; UTC

Svarbiausios naujienos

BHP: Has Concluded Iron Ore Sales Contract Negotiations With China Mineral Resources Group

2026-04-21 22:45; UTC

Svarbiausios naujienos

BHP: Pampa Norte Production Down on Ore Complexity, Variation; Declining Grades

2026-04-21 22:45; UTC

Svarbiausios naujienos

BHP: Escondida Concentrator Investment Estimated Between $4.4 Billion-$5.9 Billion

2026-04-21 22:44; UTC

Svarbiausios naujienos

BHP: Escondida Concentrator Project Seen Facing FID in 2027-28

2026-04-21 22:42; UTC

Svarbiausios naujienos

BHP CEO: Centralized Procurement, Low-cost Operations Help Buffer Industry Wide Cost Pressures

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

38.63% į viršų

12 mėnesių prognozė

Vidutinis 103.67 USD  38.63%

Aukščiausias 130 USD

Žemiausias 72 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

12

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

163 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat